A detailed history of Invesco Ltd. transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 66,086 shares of CRBU stock, worth $129,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,086
Previous 67,200 1.66%
Holding current value
$129,528
Previous $110,000 16.36%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.56 - $2.73 $1,737 - $3,041
-1,114 Reduced 1.66%
66,086 $128,000
Q2 2024

Aug 13, 2024

SELL
$1.62 - $5.05 $4,960 - $15,463
-3,062 Reduced 4.36%
67,200 $110,000
Q1 2024

May 14, 2024

SELL
$4.82 - $8.26 $32,616 - $55,895
-6,767 Reduced 8.79%
70,262 $361,000
Q4 2023

Feb 12, 2024

BUY
$3.58 - $6.25 $31,020 - $54,156
8,665 Added 12.67%
77,029 $441,000
Q3 2023

Nov 13, 2023

BUY
$4.08 - $8.14 $9,865 - $19,682
2,418 Added 3.67%
68,364 $326,000
Q2 2023

Aug 11, 2023

SELL
$4.04 - $5.47 $14,208 - $19,237
-3,517 Reduced 5.06%
65,946 $280,000
Q1 2023

May 12, 2023

BUY
$4.3 - $7.78 $206,064 - $372,833
47,922 Added 222.47%
69,463 $368,000
Q4 2022

Feb 13, 2023

SELL
$5.57 - $11.01 $1.63 Million - $3.23 Million
-293,511 Reduced 93.16%
21,541 $135,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $1.58 Million - $3.79 Million
296,643 Added 1611.4%
315,052 $3.32 Million
Q2 2022

Aug 15, 2022

BUY
$5.1 - $9.74 $32,109 - $61,323
6,296 Added 51.98%
18,409 $100,000
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $101,991 - $185,571
12,113 New
12,113 $110,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.